EFTR eFFECTOR Therapeutics
- 1.9400
- -0.0400-2.02%
- 1.9800
- +0.0400+2.06%
eFFECTOR Therapeutics News
424B3: Prospectus
8-K: Current report
4: Statement of changes in beneficial ownership of securities-Officer Byrnes Michael
4: Statement of changes in beneficial ownership of securities-Officer WORLAND STEPHEN T
SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Carlyle Group Inc.(4.1%),Carlyle Holdings I GP Inc.(4.1%), etc.
424B5: Prospectus
424B3: Prospectus
8-K/A: Current report (Amendment)
8-K: eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
8-K: Current report
10-Q: Quarterly report
ARS: Annual Report to Security Holders
DEFA14A: Others
DEF 14A: Definitive information statements
PRE 14A: Preliminary proxy statements relating to merger or acquisition
eFFECTOR Therapeutics | 424B3: Prospectus
eFFECTOR Therapeutics | 8-K: Current report
eFFECTOR Therapeutics | 424B5: Prospectus
eFFECTOR Therapeutics | EFFECT: Others
eFFECTOR Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Analysis
Price Target
No Data
